Amalgamated Bank Cuts Holdings in Balchem Co. (NASDAQ:BCPC)

Amalgamated Bank decreased its position in Balchem Co. (NASDAQ:BCPC) by 3.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,558 shares of the basic materials company’s stock after selling 334 shares during the period. Amalgamated Bank’s holdings in Balchem were worth $1,682,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. nVerses Capital LLC purchased a new stake in shares of Balchem during the third quarter worth about $35,000. Bessemer Group Inc. increased its stake in shares of Balchem by 568.9% during the first quarter. Bessemer Group Inc. now owns 301 shares of the basic materials company’s stock worth $47,000 after purchasing an additional 256 shares in the last quarter. Blue Trust Inc. increased its stake in shares of Balchem by 642.5% during the third quarter. Blue Trust Inc. now owns 839 shares of the basic materials company’s stock worth $148,000 after purchasing an additional 726 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Balchem by 73.4% during the third quarter. GAMMA Investing LLC now owns 841 shares of the basic materials company’s stock worth $148,000 after purchasing an additional 356 shares in the last quarter. Finally, Private Advisor Group LLC purchased a new stake in shares of Balchem during the third quarter worth about $220,000. Hedge funds and other institutional investors own 87.91% of the company’s stock.

Balchem Price Performance

NASDAQ:BCPC opened at $178.33 on Wednesday. The stock has a 50 day moving average price of $172.33 and a 200 day moving average price of $164.99. The stock has a market cap of $5.80 billion, a PE ratio of 47.94, a P/E/G ratio of 5.36 and a beta of 0.65. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.90 and a current ratio of 2.98. Balchem Co. has a one year low of $117.10 and a one year high of $186.03.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. StockNews.com upgraded Balchem from a “hold” rating to a “buy” rating in a report on Monday, October 28th. HC Wainwright boosted their price target on shares of Balchem from $185.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, November 4th.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.